Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Wednesday. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03, Bloomberg Earnings reports.
Shares of Syros Pharmaceuticals (SYRS) traded down 7.84% during mid-day trading on Thursday, reaching $21.05. 165,223 shares of the company were exchanged. Syros Pharmaceuticals has a 12 month low of $8.47 and a 12 month high of $24.38. The company’s 50-day moving average is $19.20 and its 200 day moving average is $15.28. The firm’s market capitalization is $551.09 million.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/2800200/syros-pharmaceuticals-inc-syrs-releases-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.
In other Syros Pharmaceuticals news, insider Eric R. Olson sold 12,500 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total value of $273,125.00. Following the completion of the transaction, the insider now owns 12,500 shares of the company’s stock, valued at $273,125. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric R. Olson sold 2,500 shares of Syros Pharmaceuticals stock in a transaction on Monday, August 7th. The stock was sold at an average price of $23.59, for a total transaction of $58,975.00. Following the completion of the transaction, the insider now directly owns 2,500 shares of the company’s stock, valued at approximately $58,975. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,282 shares of company stock valued at $404,599.
Several research analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $28.00 target price on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, June 12th. Wedbush reiterated an “outperform” rating and set a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a research note on Thursday. JMP Securities cut shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Cowen and Company reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. Finally, Zacks Investment Research cut shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $20.81.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.